Stakeholder Insight: Breast Cancer (Hormone Receptor-Negative)
Datamonitor, November 2010, Pages: 276
Triple-negative breast cancer offers a significant opportunity to new market entrants while Herceptin dominates the HER-2-positive market
While some triple-negative breast cancer (TNBC) patients now have an additional treatment option in the form of Avastin, unmet need remains high. Similarly, despite the availability of Herceptin and Tykerb there is also considerable pipeline activity in HER-2-positive breast cancer. At the same time, there is uncertainty over the optimal way of using Herceptin and Tykerb in this patient subset.
Features and benefits
- Analysis of the hormone receptor-negative breast cancer market based on a survey of 180 specialists, supported by opinion leader interviews
- Epidemiological forecasts of breast cancer incidence and prevalence for the period 2010–19 in the seven major pharmaceutical markets
- Segmentation of incident cases by age group, menopausal status, stage of disease and subtype
- In-depth analysis of treatment patterns and regimens prescribed for TNBC and HER-2-positive breast cancer by line of therapy and disease stage
Highlights
Herceptin (trastuzumab; Roche/Chugai) has established a formidable position in the HER-2-positive breast cancer market. At relapse, retreatment with an alternative Herceptin-based regimen is favored over switching to Tykerb (lapatinib; GlaxoSmithKline), reflecting the lack of clinical data showing that switching to Tykerb is beneficial.
Avastin (bevacizumab; Roche/Chugai) has captured considerable market share in first-line metastatic TNBC in the US; loss of this indication would therefore have a large impact on sales. Avastin is also vulnerable to competition from new market entrants (e.g. Sanofi Aventis’s iniparib), even if it retains its breast cancer indication.
The popularity of Xeloda (capecitabine; Roche/Chugai) shows that side-effect profile is an important driver of prescribing behavior in metastatic TNBC beyond the first-line of therapy. It is therefore critical that new market entrants in this setting are well tolerated if they are to achieve extensive uptake.
Your key questions answered
- Validate new product forecasting based on epidemiology, patient segmentation and treatment rates, and the likely rate of uptake for new products
- Understand prescribing trends and identify key factors that influence treatment choices in defined breast cancer populations
- Enhance commercial positioning by increasing understanding of current dynamics within the breast cancer market
Overview
Catalyst
Summary
Executive Summary
Scope of the analysis
Datamonitor insight into the hormone receptor-negative breast cancer market
Contributing experts
1. Introduction and Scope
Coverage of the Stakeholder Insight Survey
2. Epidemiology
Introduction and background
Key points
Disease definition and diagnosis criteria
Global variation and historical trends
Risk factors
Epidemiologic forecasting of breast cancer
Description of methods
Epidemiologic Forecast Results
Discussion
Conclusions
3. Disease overview
Introduction
Patient segmentation
4. Treatment options
Introduction
5. Treatment Trends: Stage I–III
Triple-negative breast cancer
HER-2-positive breast cancer
6. Treatment Trends: Stage IV and Relapse
Triple-negative breast cancer
HER-2-positive breast cancer
7. Future Treatment
Late-phase pipeline products overview
Future treatment scenarios
BIBLIOGRAPHY
Chapter 2. Epidemiology
Chapter 3. Disease Overview
Chapter 4. Treatment Options
Chapter 5. Treatment Trends: Stage I–III Breast Cancer
Chapter 6. Treatment Trends: Stage IV and Relapsed Breast Cancer
Chapter 7. Future Treatment
APPENDIX A
Abbreviations
Physician research methodology
Physician sample breakdown
Contributing experts
APPENDIX B
The survey questionnaire
Datamonitor consulting
Disclaimer
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
